The use of ELISA is comparable to immunoprecipitation in the detection of selected myositis-specific autoantibodies in a European population

Front Immunol. 2022 Sep 8:13:975939. doi: 10.3389/fimmu.2022.975939. eCollection 2022.

Abstract

Background: The reliable detection of myositis-specific autoantibodies (MSA) provides valuable clinical information regarding prognosis, clinical progression and diagnostic confirmation.

Objectives: To evaluate the reliability of a commercial ELISA immunoassay in detecting myositis-specific autoantibodies in comparison to immunoprecipitation as the reference standard.

Methods: Serum samples were chosen from a biobank of more than 3000 samples. Samples with a confirmed MSA on Immunoprecipitation (n=116) were evaluated in duplicate by ELISA to detect Mi2, MDA5, Jo1, EJ, KS, PL-7 and PL-12 (Medical & Biological Laboratories Co. Ltd, Nagoya, Aichi, Japan). Healthy control samples (n=246) confirmed autoantibody negative by immunoprecipitation were similarly assessed.

Results: There was a very good agreement between ELISA and immunoprecipitation for serum samples containing anti-Mi2, MDA5, Jo1, EJ, KS and PL-7 and PL-12 auto-antibodies. Cohen's κ values ranged from 0.86-1 for the measured autoantibodies on ELISA.

Conclusion: ELISA was an accurate method for detecting anti-synthetase, anti-Mi2 and anti-MDA5 autoantibodies.

Keywords: ELISA - enzyme-linked immunosorbent assay; diagnostic accuracy; diagnostic test; immunoprecipitation (IP); inflammatory myositis; myositis autoantibody.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies, Antinuclear
  • Autoantibodies*
  • Enzyme-Linked Immunosorbent Assay / methods
  • Humans
  • Immunoprecipitation
  • Myositis*
  • Reproducibility of Results

Substances

  • Antibodies, Antinuclear
  • Autoantibodies